Single-cell spatial analysis may help predict response to neoadjuvant immunotherapy in triple-negative breast cancer
A next-generation technology allows the study of protein expression at the single-cell level and...
Read MoreDec 15, 2021
A next-generation technology allows the study of protein expression at the single-cell level and...
Read MoreDec 15, 2021
Although adjuvant therapy with CDK4/6 inhibitors has shown to benefit patients with...
Read MoreDec 15, 2021
The use of multigene sequencing as a therapeutic decision tool improved the outcomes for patients...
Read MoreDec 15, 2021
The pathways leading to CDK4/6 inhibitor resistance are not yet clear. Using a technique called...
Read MoreDec 15, 2021
Development of breast cancer-related lymphedema is not equally distributed between races. Black...
Read MoreDec 15, 2021
Efficacy of second-line treatment option for patients with ER-positive/HER2-negative metastatic...
Read MoreDec 15, 2021
The phase 3 BioItaLEE trial demonstrates that pre-treatment circulating tumor DNA (ctDNA) and...
Read MoreDec 15, 2021
Adjuvant treatment with the PARP inhibitor olaparib showed beneficial effects for patients with...
Read MoreDec 15, 2021
Both patients with heavily pre-treated HR-positive/HER2-negative, HER2-mutated, metastatic breast...
Read MoreDec 15, 2021
Long-term use of tamoxifen is associated with an increased risk for the development of uterine...
Read MoreDec 15, 2021
In pre-menopausal women with early-stage, ER-positive breast cancer, adjuvant ovarian suppression...
Read MoreDec 15, 2021
Taxane with or without anthracycline reduces the recurrence rate of early-stage breast cancer. A...
Read MoreDec 14, 2021
Both adjuvant therapy with trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1) have...
Read MoreDec 14, 2021
The phase 3 RxPONDER trial evaluated the benefit of adjuvant chemotherapy followed by endocrine...
Read MoreDec 14, 2021
Among patients with HR-positive breast cancer treated with an aromatase inhibitor plus...
Read MoreDec 14, 2021
Clonal hematopoiesis of indeterminate potential (CHIP) was related to decreased risk of Alzheimer’s disease (AD) and AD neuropathological changes. Mutated hematopoietic stem cells were detected in the brains of CHIP carriers....
Read MoreDec 14, 2021
Therapy de-escalation in patients with acute lymphoblastic leukemia (ALL) and a low-risk minimal residual disease (MRD) profile was safe, 10-year follow-up results of the UKALL 2003 trial show. Patients with a high-risk MRD...
Read MoreDec 14, 2021
A combination treatment of quizartinib plus venetoclax plus decitabine was highly active in patients with relapsed/refractory FLT3-ITD-mutated acute myeloid leukemia (AML). Patients with RAS/MAPK and FLT3-F691L mutations...
Read MoreDec 14, 2021
A regimen of cladribine plus low-dose cytarabine plus venetoclax alternated with 5-azacytidine plus venetoclax showed encouraging efficacy in patients with newly diagnosed acute myeloid leukemia (AML). Moreover, the displayed...
Read MoreDec 14, 2021
A triplet combination of 5-azacitidine, venetoclax, and magrolimab displayed promising response rates in newly diagnosed older, unfit, or TP53-mutated patients with acute myeloid leukemia (AML). Moreover, the phase 1b/2 study...
Read More